Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading cause of cancer-related death worldwide, with only 20% of cases diagnosed at an early stage. Voli
02 Jul 2025
VolitionRx:Nu.Q advances in lung cancer management
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
VolitionRx:Nu.Q advances in lung cancer management
- Published:
02 Jul 2025 -
Author:
Jyoti Prakash, CFA | Pooya Hemami, OD MBA, CFA -
Pages:
14 -
Despite rapid advancements in cancer treatments, effective diagnostics for early screening and disease monitoring continue to be an unmet need. This is felt acutely in lung cancer, which is the leading cause of cancer-related death worldwide, with only 20% of cases diagnosed at an early stage. Voli